Ye, Diana Z.’s team published research in Diabetes in 2006 | CAS: 129075-56-5

5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5) belongs to isoquinoline.Name: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one Isoquinoline is a structural isomer of quinoline, and quinoline derivatives are fused ring compounds of pyridine and benzene rings, which have antiseptic, antipyretic and anti-cyclic properties, and can be used as antimalarial drugs and for the preparation of other antimalarial medicine.

Name: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-oneOn March 31, 2006, Ye, Diana Z.; Tai, Mei-Hui; Linning, Katrina D.; Szabo, Csaba; Olson, L. Karl published an article in Diabetes. The article was 《MafA expression and insulin promoter activity are induced by nicotinamide and related compounds in INS-1 pancreatic β-cells》. The article mentions the following:

Nicotinamide has been reported to induce differentiation of precursor/stem cells toward a β-cell phenotype, increase islet regeneration, and enhance insulin biosynthesis. Exposure of INS-1 β-cells to elevated glucose leads to reduced insulin gene transcription, and this is associated with diminished binding of pancreatic duodenal homeobox factor 1 (PDX-1) and mammalian homolog of avian MafA/L-Maf (MafA). Nicotinamide and other low-potency poly(ADP-ribose) polymerase (PARP) inhibitors were thus tested for their ability to restore insulin promoter activity. The low-potency PARP inhibitors nicotinamide, 3-aminobenzamide, or PD128763 increased expression of a human insulin reporter gene suppressed by elevated glucose. In contrast, the potent PARP-1 inhibitors PJ34 or INO-1001 had no effect on promoter activity. Antioxidants, including N-acetylcysteine, lipoic acid, or quercetin, only minimally induced the insulin promoter. Site-directed mutations of the human insulin promoter mapped the low-potency PARP inhibitor response to the C1 element, which serves as a MafA binding site. INS-1 cells exposed to elevated glucose had markedly reduced MafA protein and mRNA levels. Low-potency PARP inhibitors restored MafA mRNA and protein levels, but they had no affect on PDX-1 protein levels or binding activity. Increased MafA expression by low-potency PARP inhibitors was independent of increased MafA protein or mRNA stability. These data suggest that low-potency PARP inhibitors increase insulin biosynthesis, in part, through a mechanism involving increased MafA gene transcription.5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5Name: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one) was used in this study.

5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5) belongs to isoquinoline.Name: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one Isoquinoline is a structural isomer of quinoline, and quinoline derivatives are fused ring compounds of pyridine and benzene rings, which have antiseptic, antipyretic and anti-cyclic properties, and can be used as antimalarial drugs and for the preparation of other antimalarial medicine.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem